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Abstract  
Hypothesis: Heptaocellular Carcinoma is one of the most malignant human tumors and one of the 
risk factors is its high metastatic property. Coptidis Rhizoma Aqueous Extract (CRAE) is able to 
suppress the migration and invasion of hepatocellular carcinoma cells, MHCC97-L, and F-actin 
reorganization and Rho signaling inhibition is involved. Main Methods: CRAE was prepared and 
analyzed by High Performance Liquid Chromatography combined-Mass Spectrometry. The 
cytotoxicity and anti-migration action of CRAE on MHCC97-L cells were evaluated; 
Immunofluorescence and immunobloting were used to investigate the proposed mechanism of 
CRAE’s action. Key findings: Chemical analysis reveals that the active components in CRAE 
were berberine and berberine-like alkaloids. CRAE exhibits significant inhibitory effect on 
MHCC97-L cells migration as indicated by wound healing and invasion chamber assay. No 
significant alteration of matrix metalloproteinases and urokinase-type plasminogen activator (uPA) 
expression were observed in MHCC97-L cells exposed to CRAE. Reduction of F-actin 
polymerization and damage cytoskeleton network in MHCC97-L cells were observed after CRAE 
treatment. Furthermore, it was found that CRAE significantly down-regulated the Rho/ROCK 
signaling pathway. Significance: These results indicated that CRAE may act as Rho/ROCK 
signaling inhibitor to suppress MHCC97-L cells migration in vitro and suggested that total 
alkaloids in Coptidis Rhizoma may be a potential agent for suppressing liver cancer invasion. 
 
Keywords Coptidis Rhizoma, berberine, hepatocellular carcinoma, anti-metastasis, F-actin, 
Rho/ROCK signaling 
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Introduction 
 
Hepatocellular carcinoma (HCC) is one of the most prevalent human malignancies in the 
world .1-2 Each year there are approximately 500,000 new cases of HCC worldwide, 80% of which 
happens in Asia and Africa.3 HCC represents as the second common cancer in men and ninth in 
women in Hong Kong, approximately 11.8% of cancer death rate in 2002.4 One of the obstacles in 
HCC therapy is the high metastatic property of liver cancer cells. Extensive studies have tried to 
elucidate the process and mechanism involved in cancer metastasis, during which cancer cells 
migrate from one site to another. Some molecules and signaling transduction pathways have been 
identified as critical factors, such as E-cadherin, catenin, matrix metalloproteinases and the actin 
cytoskeleton,5 and molecules targeted to these factors for the sake of cancer therapy have been 
reported.6-8 However, anti-metastasis drug with effective action and clear mechanism is far from 
development.  
 
Coptidis Rhizoma (CR, Huanglian in Chinese) was a traditional Chinese medicinal herb with a 
long history of utilization in heat-clearing and toxic-scavenging. Extensive modern research on the 
pharmacological action of CR revealed its potential as an anti-inflammatory,9 anti-viral,10 
anti-bacterial11 and anti-oxidative agent.12 Our screening study demonstrated that CRAE exhibited 
the strongest inhibitory activity on the growth of tumor cells amongst sixteen anticancer 
traditional Chinese medicinal herbs.13 Moreover, our clinical study on the therapeutic effect of CR 
on liver diseases and cancer showed that CR may be used for liver cancer therapy.14. A lot of 
studies have been carried out on cytotoxic, apoptotic effects and mechanisms of CR and berberine 
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in vitro and in vivo,15 but there is no report on anti-invasive action of CR and its underlying 
mechanism. Thus, the following questions need to be clarified: Does CR have the anti-invasive 
effect? Are all signaling pathways of cancer cell migration involved in the anti-invasive effect of 
CR? Is Rho/ROCK signaling pathway specific for anti-invasive effect of CR? 
 
In this study, we reported a significant inhibitory effect of CRAE on the migration of HCC cell 
line with high metastatic property MHCC97-L cells. Using High performance liquid 
chromatogram combined with mass spectrometry (HPLC/MS), seven components were identified 
as berberine-like alkaloids in CRAE. Studies on the proposed mechanism of CRAE’s inhibition 
against MHCC97-L migration showed that the CRAE acts on actin cytoskeleton reorganization as 
Rho/ROCK inhibitor. These results shed lights on CRAE’s potential for liver cancer therapy. At 
the same time, the results also implied that berberine is a main active compound and other 
berberine-like alkaloids have synergistic anti-migration effects in CRAE.  
 
Materials and Methods 
 
Sample preparation and phytochemical analysis  
CR was collected from Sichuan province of China and authenticated as the dried roots of Coptis 
chinesis Franch. by Dr. Feng Yibin under the guidance of the Pharmacopeia of China (2005). 
Authentication was described as previous study reported and toxic elements were tested16. To 
prepare the CRAE, raw material was cut into small pieces and 500 gram of crude huanglian was 
boiled in 10 times of distilled water (w/v) at 100ْ ْC for 1 hour (three times) and then filtered. The 
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filtrate was then evaporated to dryness and the dry extract powder was collected and stored at 
-20℃ until used. Immediately before use, the extract powder was dissolved in DMSO and diluted 
to proper concentration in PBS and then sterilized by filtration through a 0.2 µm pore filter 
(Minisart®-plus, Sartorius). 
 
High performance liquid chromatography combined with mass spectrometry (HPLC/MS) was 
introduced to identify the chemical profile of CRAE. Analysis was performed using a 
reverse-phase C18 column (Alltech Alltima HP C18, 250 mm × 4.6 mm, 5 µm) as solid phase and 
methanol- Mill-Q water including 15 mM ammonium acetate (25-75) as mobile phase. The flow 
rate was 1.0 ml/min. Total ion chromatogram (TIC) of CRAE was obtained by LCQ Deca XP 
system (Thermo Finnigan, USA) using the condition as follows: Sheath Gas Flow Rat (abr):40; 
Auxiliary Gas Flow Rate (abr): 40; Spray voltage (kV): 4.5; Capillary Temperature (℃): 300; 
Capillary Voltage (V): 20; Tube Lens Offset Voltage (V):24. Immediately before analysis, 
berberine (Sigma, USA) and CRAE powder were dissolved in methanol and diluted to proper 
concentration. 1 µl of standard or sample solution was injected to HPLC-MS system and the 
content of berberine in CRAE was quantified. 
 
Cell line and Cell culture  
Human liver cancer cell line with metastatic property MHCC97-L was used in our previous 
study.17 In this study, MHCC97-L cells were maintained in Dulbecco's Modified Eagle Medium 
(DMEM) with high glucose and incubated in a humidified atmosphere containing 5% CO2 at 37 
℃. 
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Cell viability assay  
Viable cell number after CRAE treatment was obtained by MTT assay. Briefly, cells were seeded 
in 96-well plate with supplemental medium and treated with series concentration of CRAE (2, 4, 8, 
16, 32, 64, 128, 256 and 512 µM) and incubated for 24 to 72h. All experiments were conducted 
parallel with controls (0.1% DMSO). Then cells were incubated with 15 µl of 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml, Sigma, USA) at 
37℃ for 4h. Then medium was removed and 200 µl of DMSO was added to each well. The 
absorbance of formazan formed was measured at 595 nm by Multiskan MS microplate reader 
(Labsystems, Finland).  
 
Wound healing assay  
Cells were seeded in 6-well plate with 100% confluences. A gap was scrapped using a 
micro-pipette tip on the cell monolayer. Medium was refreshed and cells were exposed to 100 µM 
CRAE or berberine for 0, 24 or 48h. The migration of MHCC97-L cells were observed under 
fluorescent microscope with 40× magnification (Carl Ziess, USA). 
 
Invasion chamber assay  
Experiment was conducted under the manufacturer’s instruction (QCMTM 96-well cell invasion 
assay kit, Millipore, USA). Briefly, the invasion chamber was pre-activated by 100 µl of serum 
free medium for 1h. After rehydration of chamber, 150 µl growth medium was added to the feeder 
tray. 100 µl serum free media with 1×104 MHCC97-L cells were then placed into invasion 
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chamber. Then cells were exposed to CRAE or berberine with a series of concentrations, 12.5, 25, 
50, 100, 200 and 400 µM and incubated for 24h at 37 , 5% CO℃ 2. The amount of cells that 
invaded from the upper chamber to the feeder tray was measured using 480/520 nm filters set 
using LS55 Fluorescence/Luminescence Spectrometer (PerkinElmer, USA). 
 
MMPs assay  
The expression of matrix metalloproteinases in MHCC97-L cells with or without CRAE and 
berberine treatment was evaluated using RayBio® Human Matrix Metalloproteinase Antibody 
Array (RayBiotech, USA) under the manufacturer’s instruction. Briefly, cells were maintained in 
75-cm2 flask in serum-free medium with 80% confluence and treated with 100 µM CRAE or 
berberine for 48h. Medium and cell supernatant were collected as sample solution for subsequent 
experiment. To conduct the experiment, membranes were first incubated in 2 mL blocking buffer 
for 30 minutes. Then membranes were incubated with sample solution overnight and then rinsed 
with washing buffer. Membranes were then subsequently incubated with biotin-conjugated 
anti-MMPs and HRP-conjugated streptavidin overnight. The expression of MMPs was detected 
using detection buffer and visualized under a chemiluminescence imaging system (Biorad, USA). 
 
Visualization on F-actin reorganization by Fluorescent Microscopy  
Cells were seeded in 35mm glass bottom microwell dishes (MatTek, USA) and then exposed to 
CRAE or berberine (100, 200 µM) for 24h. Cells werer then fixed with 4% paraformaldehyde for 
30 minutes and penetrated with 1% Triton X-100 in PBS for 5 minutes, followed by 30 minutes 
incubation of 5% BSA to block the unspecific binding. 50 µg/mL FITC conjugated phalloidin 
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(Sigma, USA) was added to the chambers and cells were incubated in dark for 30 minutes. 
Nuclears were then stained with 1µg/mL DAPI for 10 minutes and cells were visualized under 
fluorescent microscope with 400× magnification (Carl Ziess, USA). 
 
RhoA-GTPase activity  
Cells were seeded in 25 cm2 flask with 80% confluence and then starved overnight in serum-free 
medium (Invitrogen, USA). After starvation, cells were treated with full growth medium with or 
without CRAE or berberine (100, 200µM) for 30 minutes. Cell lysate was collected and the 
RhoA-GTPase activity assay was conducted by Rho Activation Kit (Thermo-Pierce, USA) under 
the manufacturer’s instruction. The RhoA-GTPase and total RhoA were detected by 
immunoblotting. 
 
Immunoblotting  
Cells were harvested using a micro-scrapper (Corning, USA) and then lysed with RIPA buffer 
supplemented with protease inhibitor (1% PMSF, 0.5%apotinin and 0.5% leupeptine) and 
phosphatase inhibitor (1 mM Na3VO4 and 1mM NaF) on ice for 30 minutes and then centrifuged 
at 14,000 rpm at 4℃ for 25 minutes. Equal amounts of protein were resolved by SDS-PAGE and 
transferred onto a polyvinylidene fluoride membrane (PVDF, Biorad). Then the membrane was 
blocked with 5% BSA overnight at 4℃. The membrane was then incubated with primary antibody 
uPA, ROCK1, β-actin (Abcam, UK) at 4℃ overnight followed by incubation with appropriate 
secondary antibody (Abcam, UK) at room temperature for 2 hours. The immunoreactivites were 
detected using ECL plus kit (GE Healthcare, UK) and visualized using a chemiluminenescence 
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imaging system (Biorad, USA). 
 
Statistic analysis 
All data were analyzed by Student–T tests for the significant interrelation between treatment and 
control groups. All data were presented in terms of mean ± standard derivative (SD) of the mean. 
Differences between group means were considered to be statistically significant if values of P< 
0.05. 
 
Results 
 
Phytochemical analysis on CRAE  
Coptidis Rhizoma contains different berberine-like alkaloids including berberine, palmatine, 
jatrorrhzine, columbamine, epiberberine, and coptisine In this study, a rapid and efficient method 
was established to identify the chemical composition of the CRAE using HPLC-ESI-MS and the 
TIC profile (Fig. 1A) of the extract presents that the CRAE was mainly comprised of seven 
berberine-type compounds. Comparing the mass spectrums (Fig. 1B) with a literature report,18 
peak 1 to 7 is identified as magnoflorine, columbamine, jatrorhizine, epiberberine, copsitine, 
palmatine and berberine, respectively (Table.1). In order to facilitate comparison on the 
bioactivity between berberine and equal content of berberine of CRAE, we 
determined the total alkaloids in CRAE at 348 nm by UV spectrometric approach, 
using berberine as standard. Total alkaloids content of CRAE was expressed by equal 
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amount of berberine in the following study. 
 
The cytotoxicity of CRAE on MHCC97-L cells  
Fig. 2 shows decreased viability of MHCC97-L cells exposed to different concentrations of CRAE 
for 24, 48 or 72h, MHCC97-L cells survival was significantly inhibited after 24h incubation of 
approximately 300 µM of CRAE, and then the IC50 of CRAE decreased to about 150 µM when 
cells were treated for 48h. This result indicates that CRAE could reduce the cell survival rate in 
dose- and time- dependent manner. 
 
Effect of CRAE on the invasion and migration of MHCC97-L cells migration in vitro  
To study the anti-metastatic effect of CRAE on hepatocellular carcinoma cells MHCC97-L, 
wound healing assay and invasion chamber assay were introduced to qualitatively and 
quantitatively determine the migration of MHCC97-L cells with or without exposure of CRAE 
and its major component berberine. It was observed that MHCC97-L cells at the opposed edges of 
the wounds rapidly migrated towards each other after 48h incubation (Fig. 3A). With the increase 
of the doses, the speed of wound healing slowed down and the gap remained widely open and only 
minimum cell proliferation on the two edges of the wound was observed when cells were 
incubated with 200µM of CRAE or berberine. The cell motility was significantly inhibited in the 
presence of CRAE or its major component berberine. Similar result could be observed in invasion 
chamber assay, where both berberine and CRAE revealed inhibitory effect on the invasion of 
MHCC97-L through extracellular matrix (Fig. 3B). To further our knowledge on the CRAE’s 
action on MHCC97-L cells’ migration, cells were exposed to Y-27632, a Rho/ROCK signaling 
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inhibitor in the presence or absence of 100 µM CRAE or berberine. The result showed that 
inhibition on Rho/ROCK signaling can significantly suppress the migration of liver cancer cells 
MHCC97-L in dose dependent manner, indicating that Rho/ROCK signaling activation may play 
an important role in MHCC97-L migration. The combination of Y-27632 with CRAE increased its 
inhibitory effect at its low dose, revealing that CRAE’s action is similar to Rho/ROCK inhibitor in 
liver cancer cell migration (Fig.3C). 
 
Effect of CRAE on Matrix Metalloproteinases and uPA Expression  
It was observed that expression of MMP-2 and MMP-9 in MHCC97-L cells remained low, 
indicating a loose connection between the MMPs expression and MHCC97-L cells migration 
ability. Furthermore, both CRAE and berberine did not reduce the expression of MMP-2 and 
MMP-9 in MHCC97-L cells, but it is interesting to observe that the tissue inhibitor of matrix 
metalloproteinase-4 (TIMP-4), which was reported as an indicator in breast cancer, prostrate 
cancer and colon cancer,19 was potently inhibited by CRAE and berberine treatment (Fig.4). No 
significant change in the expression of urokinase-type plasminogen activator (uPA) in MHCC97-L 
cells with or without exposure of CRAE and berberine was also observed in our study (Fig.6), 
indicating that uPA may not involve in CRAE’s inhibitory effect on hepatocellular carcinoma 
cells’ migration. 
 
Effect of CRAE F-actin reorganization in MHCC97-L cell  
F-actin cytoskeleton in MHCC97-L was potently damaged by CRAE at the doses far lower than 
its IC50, indicating low dose of CRAE may prominently inhibit the F-actin polymerization and 
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induce damage of cytoskeleton network of MHCC97-L cells (Fig. 5).  
 
Effect of CRAE on Rho/ROCK signaling pathway 
The GTPase form of RhoA was potently suppressed in MHCC97-L with CRAE and berberine 
treatment while total RhoA expression remained constant (Fig.6), indicating that CRAE may 
suppress the activation of RhoA signaling by impeding the cycle between Rho-GDPase and 
Rho-GTPase. Moreover, CRAE exhibited prominent inhibition on the expression of ROCK-1 
(Fig.6). This further proves CRAE as inhibitor of Rho/ROCK signaling to suppress MHCC97-L 
cells migration. To confirm the role of Rho/ROCK signaling pathway on effects of CRAE in 
MHCC97-L cell migration, Y-27632, a Rho/ROCK signaling inhibitor alone or in combination to 
100 µM CRAE was used in this study and the result showed that inhibition on Rho/ROCK 
signaling could significantly suppress the migration of MHCC97-L in dose dependent manner, 
indicating that Rho/ROCK signaling activation may play an important role in MHCC97-L 
migration (Fig.3C).  
 
Discussion 
 
HCC is one of the most malignant human cancers in the world.20-21 Recurrence after surgical 
removal and metastasis are common in hepatocellular carcinoma and are associated with poor 
prognosis. Effective treatment is in urgent need for improvement of patients’ survival. Traditional 
Chinese Medicine as a complementary and alternative treatment for cancer therapy has been 
widely used in daily clinical treatment.22 As a commonly used medicinal herb, CR has been 
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extensively investigated for its potent anti-tumor action. It was reported that CR extract can inhibit 
cell proliferation by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity 
in human cancer cells.23 CR extract can induce apoptosis by up-regulating of interferon-beta and 
TNF-alpha in human breast cancer cells.24 Recently, we reported that that anti-invasion of 
berberine, pure compound isolated from CR may inhibit RhoA signaling pathway at low dose, 
while apoptosis are induced by berberine via G2 arrest at high dose in NPC cell lines due to 
berberine distribution in cell nuclear and cytoplasm in dose dependent manner.25 In this study, we 
reported the anti-invasive action of CRAE, and its major component berberine on hepatocellular 
carcinoma cells. Potent action on the F-actin reorganization and RhoA activity inhibition could be 
observed in cells with CRAE and berberine treatment. With screening on the major signal 
pathways that may involve in cancer cell migration and invasion, we found the inhibitory effect of 
CRAE and berberine on HCC cell migration is specific. Moreover, we found that CRAE, which is 
composed of seven berberine-like alkaloids, showed superior anti-invasive effect to its pure 
compound berberine. Considering that herbal extract rather than pure compound is more 
commonly used in Chinese Medicine practice14, our findings offer a potential complementary 
medication for the HCC invasion and metastasis. 
 
F-actin is one type of stress fibers that regulates cell motility and polarization. With its constant 
state of flux with new monomers being added at the ‘barbed’ or ‘plus’ end, and depolymerization 
at the ‘pointed’ or ‘minus’ end, F-actin allows eukaryotic to migrate directionally.26 In cancer cells 
with high metastatic property, active polymerization of F-actin is often reported and the reduction 
of F-actin cytoskeleton could inhibit the migration of cancer cells.27-29 In this study, we showed for 
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the first time that CRAE could effectively suppress hepatocellular carcinoma tumor migration and 
invasion in vitro and as its mechanism, we observed that CRAE acts on F-actin, inducing filament 
reorganization and inhibits Rho/ROCK signaling pathway. In a Rho/ROCK signaling induced 
cancer cells migration, cell goes through the amoeboid mode of migration. In this mode, cell 
migration is independent of integrin function and cell-substrate adhesion, which exerts pivotal 
impacts in collective and mesenchymal modes of cell migration. Cells that go through amoeboid 
migration move within the extracellular matrix by squeezing the cell body, and a rounded 
morphology can be easily observed. Inhibition of Rho/ROCK signaling was reported to induce 
elongated morphology.4 The activation of Rho small GTPases family, especially the 
RhoA-GTPase, is frequently found in the metastasis of different types of human cancers30-32, and 
inhibition of Rho-GTPase and ROCK suppresses tumor invasion in vitro and in vivo.33-36 These 
studies indicated that the Rho/ROCK signaling pathway plays a pivotal role in cancer metastasis. 
Our result indicated CRAE’s potential as an inhibitor of Rho/ROCK signaling to suppress liver 
cancer metastasis. 
 
Standard CRAE was used in this study since the clinical use form of CR is its water extract and it 
is also a basic unit to make composite formulae16,37. To standardize the quality of CRAE, 
HPLC/MS/MS was introduced in this study and we have identified seven berberine-type alkaloids 
in CRAE, in which berberine amounts approximately 23% of the total extract (data not shown). 
These results suggested that the berberine and berberine-type alkaloids may be the active 
components in CRAE for the anti-invasive effect on MHCC97-L cells. Some studies have 
revealed that CR and berberine exhibit positive correlation in their anti-cancer action in vitro and 
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in vivo.38,39 A report demonstrated that CRAE inhibits cell growth by suppressing the expression 
of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells and has better inhibitory 
effect than berberine. 40 Moreover, recent studies reported that berberine suppresses the metastasis 
and invasion lewis lung carcinoma and human lung cancer cells through the repression of 
expression of urokinase-type plasminogen activator (u-PA) or decreased production of u-PA and 
matrix metalloproteinase-2.41 Our result indicated that anti-invasive effect of CRAE on 
MHCC97-L cell line only acts on F-actin via Rho/ROCK signaling pathway, but not other 
metastasis-related molecules such as integrin beta4, E-cadherine (data not shown), u-PA and 
MMPs, indicating that the Rho/ROCK inhibition may be one new mechanism involved in its 
action against cancer invasion. The inhibitory effect of CRAE on MHCC-97L cell migration was 
observed which is consistent with berberine, but the inhibitory effect of CRAE is more potent than 
that of berberine, indicating that berberine acts as the main active compound in CRAE and other 
berberine-like alkaloids have synergistic effect to berberine. Precise role of CRAE and berberine 
on anti-metastasis in animal models needs further investigation. 
 
It was noted that berberine and CRAE used in this study were a relatively high doses. In some 
cases, the IC50 of berberine or CRAE was lower than 4 µg/ml, which is below the safety limit 
established by National Cancer Institute.40, 42 The IC50 of berberine and CRAE in this study 
seem rather high and the reason need to be further explored in future. However, berberine and 
CRAE are natural products which have been widely used for many years. As an 
anti-microbial agent, berberine has been used to cure microbial-related gastric diseases. The 
dose can be very high, even up to 1 gram per day [China Pharmacopeia, 2005 edition]. Our 
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other studies also showed that berberine revealed very low cytotoxicity on rat hepatocyte 
(data not shown) and CRAE has liver protective effect in liver damage animal model.16 These 
data suggested low toxicity of berberine and CRAE and indicated that both can be used at 
high dose. Due to the potential of berberine and Huanglian in vitro results and Chinese 
Medicine practice in the treatment of cancers, berberine and CRAE should be promising 
agents for clinical trail.15 New molecular targets, dosages of berberine and CRAE used in this 
study will provide useful information for further study. 
 
Conclusion 
 
In conclusion, this is the first time to show that CRAE is a potent anti-metastatic agent to inhibit 
MHCC97-L cells which is a high invasive cell model for liver cancer. CRAE has better 
antiinvasive effect than its main active compound, berberine, suggesting that other berberine-like 
alkaloids have synergistic effect to berberine. CRAE acts on F-actin, inducing filament 
reorganization and therefore inhibits MHCC97-L cell motility. The inactivation of Rho/ROCK 
signaling pathway involved in CRAE’s inhibitory action on MHCC97-L migration indicated 
CRAE’s role as Rho-small GTPase inhibitor. This study sheds light on CRAE as an alternative 
therapy for the treatment of metastatic hepatic carcinoma. 
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Figure legends  
 
Fig.1 Chemical analysis of CRAE by HPLC/MS/MS. A shows the HPLC/MS/MS TIC 
chromatogram of CRAE; B shows the mass spectrums of particular peaks in TIC chromatogram of 
CRAE. 
 
Fig.2 MHCC97-L cells viability after CRAE treatment in different dose and time (MTT assay) 
(*p<0.05, **p<0.01 when compared with control) 
 
Fig.3 CRAE and Berberine significantly inhibits the migration of liver cancer cells MHCC97-L. A 
shows results of wound healing assay, presenting that low dose of CRAE and berberine can 
suppress MHCC97-L cells migrating from distinct edges to center. B shows results of invasion 
chamber assay, indicating that CRAE and berberine inhibit MHCC97-L cells migration in 
dose-dependent manner. (*p<0.05, **p<0.01 when compared with control) C shows that addition 
of Y-27632, a Rho/ROCK inhibitor alone or in combination of CRAE, can dose-dependently 
suppress the migration of MHCC97-L. The left three panels showed cell migration in Fig. 3C, in 
which the first one is without any treatment, the second and third ones showed the effect of low 
and high dose of Y-27632 treatment alone. This figure indicates that high dose of Y-27632 could 
completely suppress MHCC97-L cell migration. The figure also reveals that Rho/ROCK inhibition, 
which showed berberine and CRAE have the similar action could suppress cancer cell migration. 
The right two panels in Fig. 3C showed that combination of low dose of berberine or CRAE and 
Y-27632 increased their inhibitory effect at their low dose compared with Fig.3A, revealing that 
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action of berberine and CRAE is similar to Rho/ROCK inhibitor in liver cancer cell migration. 
 
Fig.4 The expression of MMPs in MHCC97-LL cell treated with 100 µM berberine (B), 100 µM 
CRAE (C) or vehicle (A). The graph shows the inhibition of CRAE on the expression of TIMP-4 
but no suppression on MMP-2 and MMP-9. 
 
Fig.5 CRAE and berberine affect F-actin reorganization and therefore inhibit MHCC97-L cell 
motility. 
 
Fig.6 Immunobloting of Rho/ROCK signaling pathway in MHCC97-L cell. A shows that CRAE 
and berberine exhibited a dose-dependent inhibitory effect on the activation of RhoA-GTPase and 
ROCK-1 expression, indicating its action on F-actin reorganization may be through its 
suppression on Rho/ROCK signal transduction. B shows a quantitative analysis on the western 
blot results. (**p<0.01 when compared with CTL group)
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Table. 1 Chemical identification of Alkaloid in CRAE 
Peak 
No. 
Retention 
Time 
(min) 
Characteristic Fragmentation 
(CF) 
CR in literature[17] 
chemical 
identification 
molecular 
weight 
1 4.3 342.1,297.1,282.1,265.1,222.1 342.1705,297.1115,282.0886,265.0858,222.0672 magnoflorine 342 
2 7.26 322.2,308.2,294.2,279.2 322.1063,308.0907,294.1107,280.0958 columbamine 338 
3 10.02 338.1,323.2,308.1,294.3,280.2 338.1375,323.1135,308.0907,294.1107,280.0958 jatrorrhizine 338 
4 10.68 336.2,320.2,292.3, 336.1219,320.0966,292.0950 epiberberine 336 
5 11.67 320.3,292.3,290.3,262.3 320.0910,292.0959,290.0804,262.0856 copsitine 320 
6 16.04 352.2,337.3,336.2,308.2,294.3 352.1536,337.1295,336.1224,308.1252,294.1113 palmatine 352 
7 17.39 336.2,320.3,306.1,292.3,278.3 336.1217,320.0904,306.0755,292.0953,278.0801 berberine 336 
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